Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 11/20 | 0.53 |
| ▸ | FLT1 | P17948 | 10/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.53 |
| ▸ | KIT | P10721 | 6/20 | 0.53 |
| ▸ | CSF1R | P07333 | 2/20 | 0.53 |
| ▸ | FLT4 | P35916 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | HLA-A | P04439 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | STK3 | Q13188 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.38 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481851 | 0.89 | CYP19A1 (0.53) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL871138 | 0.89 | CYP19A1 (0.53) | KDRFLT1PDGFRBKITCSF1R | |
| Hydrochloric Acid SCHEMBL6061889 | 0.87 | CYP19A1 (0.52) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL31738482 | 0.81 | CYP19A1 (0.61) | CYP19A1ALDH1A1MAPT | |
| SCHEMBL7069713 | 0.81 | CYP19A1 (0.61) | CYP19A1ALDH1A1MAPT | |
| Succinic Acid SCHEMBL27650673 | 0.81 | SMN1; SMN2 (0.44) | KDRCYP19A1EGFRALDH1A1MAPT | |
| SCHEMBL17241010 | 0.79 | CYP1A2 (0.49) | KDRCYP19A1EGFRTBXAS1ALDH1A1 | |
| SCHEMBL6467224 | 0.79 | EGFR (0.43) | KDRCYP19A1EGFRALDH1A1MAPT | |
| 4-Chloroaniline SCHEMBL27513988 | 0.77 | FLT1 (0.53) | KDRFLT1PDGFRBKITCSF1R | |
| SCHEMBL1814398 | 0.75 | TDP1 (0.47) | KDRCYP19A1EGFRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298098-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023056589-A1 | MENIN INHIBITORS AND METHODS OF USE FOR TREATING CANCER | SERVIER PHARMACEUTICALS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| WO-2022161496-A1 | SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-08-04 | — | — | WO | disclosed |
| EP-3781575-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781570-A1 | MACROCYCLIC INDOLES AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781574-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020151738-A1 | MACROCYCLIC FUSED PYRRAZOLES AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020147802-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
| WO-2019179482-A1 | 5, 6-DIHYDRO-11H-INDOLO [2, 3-B] QUINOLIN-11-ONE COMPOUNDS AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-09-26 | — | — | WO | disclosed |